Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06344065
Other study ID # 20220102C
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date December 21, 2023
Est. completion date December 25, 2028

Study information

Verified date February 2024
Source Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Contact Wenjian Fang
Phone +86-18611630252
Email fangwenjian@zhifeishengwu.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and immunogenicity of the DTaP in 3-month-old infants.


Description:

This is a Phase III, Single Center, Randomized, Blind, and Positive Control Clinical Trial conducted in Guangxi Province, China. The purpose of this study is to evaluate the safety and immunogenicity of Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine (Adsorbed) in 3-month-old infants. Expected to include 1584 3-month-old infants. Among them, 1056 infants were randomly assigned to the experimental group and active control group 1, and 528 infants were included in active control group 2. Select the top 200 subjects with study numbers from the experimental group as immunological persistence follow-up subset.


Recruitment information / eligibility

Status Recruiting
Enrollment 1584
Est. completion date December 25, 2028
Est. primary completion date May 25, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Months to 3 Months
Eligibility Inclusion Criteria: - Basic immune stage: 1. 3-month-old infants who can provide valid identification documents; 2. Infants should be born following a 37-42 weeks of pregnancy and have a birth weight that meets the standard (2500g = body weight = 4500g); 3. The legal guardian of the subject voluntarily agrees to their child's participation in the trial and signs a written informed consent form; 4. The legal guardian of the subject has the ability to understand the trial procedure and participate in all planned follow-up visits; 5. Has not received a vaccine containing the active ingredients of pertussis, diphtheria, tetanus combined vaccine; 6. Active control group 2 has not been vaccinated with any vaccine containing the active ingredients of poliomyelitis vaccine or haemophilus influenzae vaccine; - Enhanced immunity stage: 1. Infants and young children aged 18-24 months who have been enrolled in this clinical trial at the age of 3 months; 2. Basic immunization has been completed in this clinical trial; 3. According to the researcher's opinion, the subjects and their legal guardians are able to comply with the requirements of the clinical trial protocol. Exclusion Criteria: - Basic immune stage: 1. Has a history of pertussis, diphtheria, or tetanus; 2. Has any history of severe allergies to vaccination in the past; 3. Allergy to any component of the experimental vaccine; 4. Has a history or family history of epilepsy, convulsions, encephalopathy, mental illness; 5. Individuals with thrombocytopenia, any coagulation dysfunction, or undergoing anticoagulant therapy that may cause contraindications for subcutaneous injection; 6. Suffering from serious congenital malformations or serious diseases that may interfere with the conduct or completion of the trial including but not limited to: infant wheezing, Down syndrome, severe thalassemia, heart disease, liver disease, kidney disease, diabetes, hereditary allergies, Guillain Barre syndrome, severe skin diseases, congenital or acquired immune defects (repeated perianal abscess), etc; 7. Has the history of severe abnormal production process, suffocation rescue, neurological damage, and current pathological jaundice; 8. Suffering from infectious diseases with clinical or serological evidence, such as tuberculosis, hepatitis B, hepatitis C, or HIV infection confirmed by parents; 9. Within 3 months before to enrollment, has received systemic corticosteroid treatment (any route of administration, = 2mg/kg/day) for = 14 days, such as prednisone, inhaled steroids such as budesonide, and fluticasone; Or being using other immunosuppressants such as cyclosporine, tacrolimus, etc. before enrollment; 10. Within 3 months before enrollment,has received treatment with immunoglobulin and/or any blood products (except hepatitis B immunoglobulin) ; 11. Participating in or planning to participate in clinical trials of other drugs in the near future; 12. According to the researcher's judgment, there are any other factors that are not suitable for the subjects to participate in the clinical trial. - Enhanced immunity stage: 1. Newly discovered severe allergic history to any previous vaccination; 2. Individuals with thrombocytopenia, any coagulation dysfunction, or undergoing anticoagulant therapy that may cause contraindications for subcutaneous injection; 3. Suffering from serious congenital malformations or serious diseases that may interfere with the conduct or completion of the test, including but not limited to: infant wheezing, Down syndrome, severe thalassemia, heart disease, liver disease, kidney disease, diabetes, hereditary allergies, Guillain Barre syndrome, severe skin diseases, congenital or acquired immune defects (repeated perianal abscess), etc; 4. After completing basic immunization, subjects were vaccinated with other vaccine containing the active ingredients of pertussis, diphtheria, tetanus combined vaccine before booster immunization; 5. Participating in or planning to participate in clinical trials of other drugs in the near future; 6. According to the researcher's judgment, there are any other factors that are not suitable for the subjects to participate in the clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Diphtheria, tetanus and acellular pertussis (component) combined vaccine (adsorbed)
Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for experimental vaccine is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
Diphtheria, tetanus and acellular pertussis combined vaccine (adsorbed)
Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 1 is intramuscular injection of 0.5ml into the lateral deltoid muscle of the upper arm.
Diphtheria, tetanus, pertussis (acellular, component), poliomyelitis (inactivated) vaccine (adsorbed) and Haemophilus influenzae type b conjugate vaccine
Three doses of basic immunization were administered at 3, 4, and 5 months of age, and one dose of booster immunization was administered at 18-24 months of age, for a total of four doses. The administration route for active control vaccine 2 is through intramuscular injection of 0.5ml into the anterolateral side of the thigh or the upper arm.

Locations

Country Name City State
China Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention Nanning Guangxi

Sponsors (1)

Lead Sponsor Collaborator
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity results of experimental group and active control group (DTaP) Positive conversion rate (4-fold increase) of antibodies against diphtheria (anti D) and tetanus (anti T) 30 days after basic immunization
Primary Immunogenicity results of experimental group and active control group (DTaP-IPV//PRP-T) Positive conversion rate (4-fold increase) of pertussis toxin antibody (anti PT), pertussis filamentous hemagglutinin antibody (anti FHA) antibodies 30 days after basic immunization
Primary Immunogenicity results of experimental group Positive conversion rate of pertussis adhesin antibody (anti PRN) 30 days after basic immunization
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1